Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II safety, tolerability and pharmacokinetics of second-generation VIR-7831 in non-hospitalized mild to moderate COVID-19
2021-000724-35Phase 2Completed
- Sponsor
- Vir Biotechnology
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sotrovimab in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Vir Biotechnology. Primary endpoint: Occurrence of adverse events through Day 29. Started Mar 2021; status: completed.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000724-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000724-35.